펜형 및 주입기형 약물전달 디바이스 시장 규모, 점유율과 동향 분석 보고서 : 제품별, 치료 용도별, 최종 용도별, 지역별, 부문 예측(2026-2033년)

Pen And Injector Drug Delivery Devices Market Summary

The global pen and injector drug delivery devices market size was estimated at USD 114.67 billion in 2025 and is projected to reach USD 236.54 billion by 2033, growing at a CAGR of 9.6% from 2026 to 2033. This strong growth is driven by the rising demand for advanced, effective, and user-friendly drug delivery solutions across healthcare settings..

Key drivers include the increasing prevalence of chronic conditions such as diabetes, cancer, and autoimmune disorders that require frequent injections; growing adoption of user-friendly injection tools such as autoinjectors and pen injectors; and continuous technological advancements that enhance safety, accuracy, and patient comfort. In addition, growing biological development, the shift toward home-based care, and greater focus on reducing hospital visits are further supporting market growth.

One of the major drivers of the pen and injector drug delivery devices market is the increasing prevalence of chronic diseases, along with the rapid growth of the geriatric population. Chronic conditions such as diabetes, cancer, cardiovascular diseases, and autoimmune disorders often require regular or long-term medication delivered through injections for fast and effective therapeutic action. According to the IDF's 2021 report, about 537 million people around the world had diabetes, which means roughly 1 in 10 people were affected. The number is expected to rise sharply, reaching 783 million people by 2045. As these diseases become more common in the world, the demand for reliable and easy-to-use injectable devices continues to increase. In addition, the aging population faces multiple health issues and typically requires frequent medical treatments, including injectable drugs. According to the recent population estimates and projections by UN DESA's Population Division, the number of people aged 60 and older is projected to reach 1.5 billion by 2050, representing about 1 in 6 people globally. This demographic shift is supporting the need for convenient, safe, and precise delivery systems that support both clinical use and home-based care, thereby contributing significantly to market growth.

Technological advancements in drug delivery systems are driving the growth of pen and injector drug delivery devices. Innovations have made injection devices safer, more efficient, and easier for patients to use. Features such as smart autoinjectors with digital monitoring, needle-free injection technologies, and improved safety mechanisms help ensure accurate dosing and reduce the risk of needle injuries. Advancements in materials and device design also enhance comfort and support self-use at home, which is becoming increasingly important for people managing chronic diseases. For instance, in October 2024, BD and Ypsomed announced a strategic collaboration to integrate BD's Neopak XtraFlow glass prefillable syringe, featuring a shorter 8 mm needle and a thinner-wall cannula, with Ypsomed's YpsoMate 2.25 autoinjector. This design makes high-viscosity biologic drugs easier to inject for patients self-administering at home, and the two-step injector is purpose-built to assist users with

limited grip or vision. Such technological improvements encourage adoption and support significant market growth.

Global Pen And Injector Drug Delivery Devices Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pen and injector drug delivery devices market report on the basis of product, therapeutic use, end use, and region.

• Product Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)
• Injectors
  • GLP-1 Agonists
  • Hormone Therapies
  • Biologics
  • Others
• Pen
  • GLP-1 Agonists
  • Insulin
  • Hormone Therapies
  • Others
• Therapeutic Use Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)
• Autoimmune Disorders
• Hormonal Disorders
• Oncology
• Obesity
• Diabetes Mellitus
• Others
• End Use Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)
• Hospitals
• Homecare Settings
• Others
• Regional Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Sweden
  • Denmark
• Asia
  • China
  • Japan
  • India
  • Thailand
  • South Korea
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product
  • 1.2.2. Drug Type
  • 1.2.3. Therapeutic Use
  • 1.2.4. End Use
• 1.3. Estimation and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Materials & Third-Party Perspectives
  • 1.5.4. Primary Research
• 1.6. Information or Data Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Validation
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
    • 1.8.1.1. Research Scope and Assumptions
    • 1.8.1.2. Research Methodology and Assumptions
  • 1.8.2. Volume Price Analysis
  • 1.8.3. CDMO Pen and Injector Drug Delivery Devices Market
• 1.9. List of Secondary Sources
• 1.10. List of Abbreviations
• 1.11. Objectives
  • 1.11.1. Objective 1
  • 1.11.2. Objective 2
  • 1.11.3. Objective 3

Chapter 2. Executive Summary

• 2.1. Market Snapshot (Regional)
• 2.2. Segment Snapshot (Product)
• 2.3. Segment Snapshot (Therapeutic Use)
• 2.4. Segment Snapshot (End Use)
• 2.5. Market Concentration

Chapter 3. Pen and Injector Drug Delivery Devices Market Variables and Trends Market Lineage Outlook

• 3.1. Market Dynamics
  • 3.1.1. Market Driver Impact Analysis
  • 3.1.2. Market Restraint Analysis
  • 3.1.3. Market Opportunity Analysis
• 3.2. Industry Analysis Tools
  • 3.2.1. Porter's Five Forces Analysis
  • 3.2.2. Macroeconomic Analysis
• 3.3. List of CDMO Manufacturers and Supplied Pen and Injector Drug Delivery Devices to Companies
• 3.4. List of In-House Manufacturers of Pen and Injector Drug Delivery Devices
• 3.5. Qualitative Insights on Potential Impact of New Injectables or Oral Drugs and Development of Multi-Dose Devices, by Region
  • 3.5.1. North America
  • 3.5.2. Europe
  • 3.5.3. Asia
• 3.6. Global CDMO Pen and Injector Drug Delivery Devices Market, by Product, 2021-2033 (value in USD Billion and Volume in Units Sold)
  • 3.6.1. Global CDMO Pen and Injector Drug Delivery Devices Market, by Product, 2021- 2033 (USD Billion)
  • 3.6.2. Global CDMO Pen and Injector Drug Delivery Devices Market, by Product, 2021- 2033 (Units)

Chapter 4. Pen and Injector Drug Delivery Devices Market: Product Analysis

• 4.1. Product Movement Analysis & Market Share, 2025 & 2033
• 4.2. Pen and Injector Drug Delivery Devices Market Estimates & Forecast, by Product (USD Billion, Units)
• 4.3. Market Size & Forecasts and Trend Analysis, 2021 to 2033
  • 4.3.1. Injectors
    • 4.3.1.1. Injectors Market, 2021 - 2033 (USD Billion, Units)
    • 4.3.1.2. GLP-1 Agonists
      • 4.3.1.2.1. GLP-1 Agonists Market, 2021 to 2033 (USD Billion, Units)
    • 4.3.1.3. Hormone Therapies
      • 4.3.1.3.1. Hormone Therapies Market, 2021 to 2033 (USD Billion, Units)
    • 4.3.1.4. Biologics
      • 4.3.1.4.1. Biologics Market, 2021 to 2033 (USD Billion, Units)
    • 4.3.1.5. Others
      • 4.3.1.5.1. Others Market, 2021 to 2033 (USD Billion, Units)
  • 4.3.2. Pen
    • 4.3.2.1. Pens Market, 2021 - 2033 (USD Billion, Units)
    • 4.3.2.2. GLP-1 Agonists
      • 4.3.2.2.1. GLP-1 Agonists Market, 2021 to 2033 (USD Billion, Units)
    • 4.3.2.3. Insulin
      • 4.3.2.3.1. Insulin Market, 2021 to 2033 (USD Billion, Units)
    • 4.3.2.4. Hormone Therapies
      • 4.3.2.4.1. Hormone Therapies Market, 2021 to 2033 (USD Billion, Units)
    • 4.3.2.5. Others
      • 4.3.2.5.1. Other Market Estimates & Forecasts, 2021 to 2033 (USD Billion, Units)

Chapter 5. Pen and Injector Drug Delivery Devices Market: Therapeutic Use Estimates & Trend Analysis

• 5.1. Therapeutic Area Movement Analysis & Market Share, 2025 & 2033
• 5.2. Pen and Injector Drug Delivery Devices Market Estimates & Forecast, by Therapeutic Use (USD Billion, Units)
• 5.3. Market Size & Forecasts and Trend Analysis, 2021 to 2033
  • 5.3.1. Autoimmune Disorders
    • 5.3.1.1. Autoimmune Disorders Market, 2021 to 2033 (USD Billion, Units)
  • 5.3.2. Hormonal Disorders
    • 5.3.2.1. Hormonal Disorders Market, 2021 to 2033 (USD Billion, Units)
  • 5.3.3. Oncology
    • 5.3.3.1. Oncology Market, 2021 to 2033 (USD Billion, Units)
  • 5.3.4. Obesity
    • 5.3.4.1. Obesity Market, 2021 to 2033 (USD Billion, Units)
  • 5.3.5. Diabetes Mellitus
    • 5.3.5.1. Diabetes Mellitus Market, 2021 to 2033 (USD Billion, Units)
  • 5.3.6. Others
    • 5.3.6.1. Others Market, 2021 to 2033 (USD Billion, Units)

Chapter 6. Pen and Injector Drug Delivery Devices Market: End Use Analysis

• 6.1. End Use Movement Analysis & Market Share, 2025 & 2033
• 6.2. Pen and Injector Drug Delivery Devices Market Estimates & Forecast, by End Use (USD Billion, Units)
• 6.3. Market Size & Forecasts and Trend Analysis, 2021 to 2033
  • 6.3.1. Hospitals
    • 6.3.1.1. Hospitals Market, 2021 to 2033 (USD Billion, Units)
  • 6.3.2. Homecare Settings
    • 6.3.2.1. Homecare Settings Market, 2021 to 2033 (USD Billion, Units)
  • 6.3.3. Others
    • 6.3.3.1. Others Market, 2021 to 2033 (USD Billion, Units)

Chapter 7. Pen and Injector Drug Delivery Devices Market: Regional Estimates & Trend Analysis

• 7.1. Pen and Injector Drug Delivery Devices Market: Regional Outlook
• 7.2. North America
  • 7.2.1. North America Pen and Injector Drug Delivery Devices Market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.2.2. U.S.
    • 7.2.2.1. Competitive Scenario
    • 7.2.2.2. Regulatory framework
    • 7.2.2.3. Reimbursement Structure
    • 7.2.2.4. U.S. Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.2.3. Canada
    • 7.2.3.1. Competitive Scenario
    • 7.2.3.2. Regulatory framework
    • 7.2.3.3. Reimbursement Structure
    • 7.2.3.4. Canada Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.2.4. Mexico
    • 7.2.4.1. Competitive Scenario
    • 7.2.4.2. Regulatory framework
    • 7.2.4.3. Reimbursement Structure
    • 7.2.4.4. Mexico Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
• 7.3. Europe
  • 7.3.1. Europe Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.3.2. UK
    • 7.3.2.1. Competitive Scenario
    • 7.3.2.2. Regulatory framework
    • 7.3.2.3. Reimbursement Structure
    • 7.3.2.4. UK Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.3.3. Germany
    • 7.3.3.1. Competitive Scenario
    • 7.3.3.2. Regulatory framework
    • 7.3.3.3. Reimbursement Structure
    • 7.3.3.4. Germany Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.3.4. France
    • 7.3.4.1. Competitive Scenario
    • 7.3.4.2. Regulatory framework
    • 7.3.4.3. Reimbursement Structure
    • 7.3.4.4. France Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.3.5. Italy
    • 7.3.5.1. Competitive Scenario
    • 7.3.5.2. Regulatory framework
    • 7.3.5.3. Reimbursement Structure
    • 7.3.5.4. Italy Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.3.6. Spain
    • 7.3.6.1. Competitive Scenario
    • 7.3.6.2. Regulatory framework
    • 7.3.6.3. Reimbursement Structure
    • 7.3.6.4. Spain Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.3.7. Norway
    • 7.3.7.1. Competitive Scenario
    • 7.3.7.2. Regulatory framework
    • 7.3.7.3. Reimbursement Structure
    • 7.3.7.4. Norway Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.3.8. Sweden
    • 7.3.8.1. Competitive Scenario
    • 7.3.8.2. Regulatory framework
    • 7.3.8.3. Reimbursement Structure
    • 7.3.8.4. Sweden Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.3.9. Denmark
    • 7.3.9.1. Competitive Scenario
    • 7.3.9.2. Regulatory framework
    • 7.3.9.3. Reimbursement Structure
    • 7.3.9.4. Denmark Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
• 7.4. Asia
  • 7.4.1. Asia Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.4.2. China
    • 7.4.2.1. Competitive Scenario
    • 7.4.2.2. Regulatory framework
    • 7.4.2.3. Reimbursement Structure
    • 7.4.2.4. China Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.4.3. Japan
    • 7.4.3.1. Competitive Scenario
    • 7.4.3.2. Regulatory framework
    • 7.4.3.3. Reimbursement Structure
    • 7.4.3.4. Japan Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.4.4. India
    • 7.4.4.1. Competitive Scenario
    • 7.4.4.2. Regulatory framework
    • 7.4.4.3. Reimbursement Structure
    • 7.4.4.4. India Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.4.5. Thailand
    • 7.4.5.1. Competitive Scenario
    • 7.4.5.2. Regulatory framework
    • 7.4.5.3. Reimbursement Structure
    • 7.4.5.4. Thailand Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.4.6. South Korea
    • 7.4.6.1. Competitive Scenario
    • 7.4.6.2. Regulatory framework
    • 7.4.6.3. Reimbursement Structure
    • 7.4.6.4. South Korea Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.4.7. Saudi Arabia
    • 7.4.7.1. Competitive Scenario
    • 7.4.7.2. Regulatory framework
    • 7.4.7.3. Reimbursement Structure
    • 7.4.7.4. Saudi Arabia Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.4.8. UAE
    • 7.4.8.1. Competitive Scenario
    • 7.4.8.2. Regulatory framework
    • 7.4.8.3. Reimbursement Structure
    • 7.4.8.4. UAE Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.4.9. Kuwait
    • 7.4.9.1. Competitive Scenario
    • 7.4.9.2. Regulatory framework
    • 7.4.9.3. Reimbursement Structure
    • 7.4.9.4. Kuwait Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)

Chapter 8. Pen and Injector Drug Delivery Devices Market: Competitive Analysis

• 8.1. Company Categorization
• 8.2. Participant's Overview
• 8.3. Financial Performance
• 8.4. Product Offerings
• 8.5. Company Market Position Analysis
• 8.6. Company Market Share Analysis, 2024 (%)
• 8.7. Strategy Mapping
  • 8.7.1. Product Launches & Approvals
  • 8.7.2. Partnerships & Collaborations
  • 8.7.3. Mergers & Acquisitions
  • 8.7.4. Expansions
  • 8.7.5. Others
• 8.8. Company Profiles
  • 8.8.1. Novo Nordisk A/S
    • 8.8.1.1. Company Overview
    • 8.8.1.2. Financial Performance
    • 8.8.1.3. Product Benchmarking
    • 8.8.1.4. Strategic Initiatives
  • 8.8.2. Sanofi
    • 8.8.2.1. Company Overview
    • 8.8.2.2. Financial Performance
    • 8.8.2.3. Product Benchmarking
    • 8.8.2.4. Strategic Initiatives
  • 8.8.3. Eli Lilly and Company
    • 8.8.3.1. Company Overview
    • 8.8.3.2. Financial Performance
    • 8.8.3.3. Product Benchmarking
    • 8.8.3.4. Strategic Initiatives
  • 8.8.4. AstraZeneca plc
    • 8.8.4.1. Company Overview
    • 8.8.4.2. Financial Performance
    • 8.8.4.3. Product Benchmarking
    • 8.8.4.4. Strategic Initiatives
  • 8.8.5. Pfizer, Inc.
    • 8.8.5.1. Company Overview
    • 8.8.5.2. Financial Performance
    • 8.8.5.3. Product Benchmarking
    • 8.8.5.4. Strategic Initiatives
  • 8.8.6. Merck KGaA
    • 8.8.6.1. Company Overview
    • 8.8.6.2. Financial Performance
    • 8.8.6.3. Product Benchmarking
    • 8.8.6.4. Strategic Initiatives
  • 8.8.7. Teva Pharmaceuticals
    • 8.8.7.1. Company Overview
    • 8.8.7.2. Financial Performance
    • 8.8.7.3. Product Benchmarking
    • 8.8.7.4. Strategic Initiatives
  • 8.8.8. Amgen, Inc.
    • 8.8.8.1. Company Overview
    • 8.8.8.2. Financial Performance
    • 8.8.8.3. Product Benchmarking
    • 8.8.8.4. Strategic Initiatives
  • 8.8.9. Ferring Pharmaceuticals
    • 8.8.9.1. Company Overview
    • 8.8.9.2. Financial Performance
    • 8.8.9.3. Product Benchmarking
    • 8.8.9.4. Strategic Initiatives
  • 8.8.10. AbbVie, Inc.
    • 8.8.10.1. Company Overview
    • 8.8.10.2. Financial Performance
    • 8.8.10.3. Product Benchmarking
    • 8.8.10.4. Strategic Initiatives